The first blood test able to detect early-stage Breast Cancer
The US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its blood test to detect early-stage Breast Cancer. The Breakthrough Designation is granted by the US FDA for devices that demonstrate a potential for more effective diagnosis of life-threatening diseases such as cancer. The objective of the Breakthrough Devices Program is to provide patients and healthcare providers with timely access to medical devices granted such designation by expedited development, assessment, and review. Trucheck™ The test uses a proprietary technology developed by the Company to detect Circulating Tumor Cells (CTCs) specific to Breast Cancer. Studies have shown that the test can detect even Stage 0 (DCIS) and Stage 1 cancers with high accuracy. The test requires only 5 ml blood and is indicated for asymptomatic women above the age of 40 years with a physician's prescription.
Globally, more than 2.3 million women develop breast cancer each year, and early detection is considered critical to their cure. In Bulgaria, this test can be done at the Hill Clinic - Sofia. All you have to do is give us a call on 02 439 3131 and we'll provide all the information you need
Datar Cancer Genetics and Hill clinic are registered trademarks
* Hill Clinic @ 2023 All rights reserved.